Purpose: To evaluate a chemoreduction regimen using systemic vincristine and carboplatin (VC) and local ophthalmic therapies to avoid external-beam radiotherapy (EBRT) or enucleation in patients with Group B intraocular retinoblastoma.
INTRODUCTION
Retinoblastoma occurs in 6% of children with cancer less than 5 years of age. 1 Enucleation and external beam radiotherapy enabled survival to increase from 30% in the 1930s to almost 100% at the present time in high-income countries, 2, 3 but this increased survival is accompanied by long-term morbidity and mortality. Survivors are at risk for visual impairment, cataract, dry eye, midface and orbital deformities, and, most significantly, subsequent neoplasms (SMNs). [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] In order to avoid these complications, retinoblastoma therapy has undergone a dramatic change during the past two decades, with the introduction of systemic chemotherapy (chemoreduction) together with local ophthalmic therapies and, more recently, regionally administered subtenon and selective intraarterial and intravitreal chemotherapy. 3, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Data from studies utilizing carboplatin and etoposide with or without vincristine demonstrated excellent results for patients with ReeseEllsworth Groups I-III or International Classification Group A and B, [17] [18] [19] [20] [21] [22] [23] [24] but concern about the use of etoposide has been raised due to its association with secondary leukemia. The Cancer Therapy Evaluation Program of the National Cancer Institute (NCI) reported cumulative 6-year incidence rates of secondary leukemia for low, moderate, and higher cumulative etoposide dose groups of 3.3%, 0.7%, and 2.2%, respectively, 30 with most intraocular retinoblastoma chemotherapy regimens falling into the low-dose group. In a review of children treated for retinoblastoma, 15 cases of therapy-related acute myeloblastic leukemia were identified, eight of whom had received etoposide although, together with other chemotherapy agents, not in a regimen of six cycles of carboplatin, etoposide, and vincristine alone. 9 Therefore, we designed this study to assess the efficacy of a systemic chemotherapy regimen for patients with unilateral or bilateral Group B retinoblastoma that did not include systemic etoposide.
PATIENTS AND METHODS
Children's Oncology Group (COG) ARET0331, approved by the National Cancer Institute (NCI) Adult/Pediatric Central Institutional Review Board (IRB) and at the IRBs of participating sites, was a single arm trial, comparing the event-free survival (EFS) experience of the patients receiving the proposed treatment with the EFS expected with regimens that included carboplatin, etoposide, and vincristine.
After undergoing an evaluation under anesthesia (EUA) to confirm disease and eligibility, patients were treated with one cycle of vincristine and carboplatin (VC), without local ophthalmic therapy, to assess early response to systemic chemotherapy. At the conclusion of the first cycle of chemotherapy, patients were evaluated by ophthalmoscopy for response. Those who had no progression of disease continued to receive this two-drug therapy for a total of six cycles. Patients continued to receive EUAs at least every two cycles to assess response. Additional ophthalmic examinations were performed at the discretion of the treating ophthalmologist. All systemic chemotherapy delivered in cycles 2 through 6 could be accompanied by local ophthalmic therapies, such as cryotherapy, diode laser thermotherapy, or episcleral plaque radiotherapy (brachytherapy), as required. Most treating ophthalmologists administered these therapies to areas of active tumor with each cycle of chemotherapy, delivered 28 days apart. The study schema is shown in Figure 1 . The primary objective of the study was to estimate the 2-year EFS, where an event was defined as the need for nonprotocol therapy, which included (i) the use of any systemic chemotherapy F I G U R E 1 Experimental design schema. Local therapy: cryotherapy, diode laser thermotherapy, episcleral plaque radiotherapy (alone or in combination) V, vincristine; C, carboplatin other than vincristine or carboplatin as defined in the protocol, (ii) enucleation, or (iii) external beam radiation (EBRT).
Patients were eligible for the study if they were less than 6 years old, newly diagnosed with Group B intraocular retinoblastoma and had not received any prior antineoplastic or local ophthalmic therapy. These included patients with unilateral disease with a Group B tumor, or bilateral disease with a Group B tumor in one eye and either a Group A, B, or an already enucleated other eye. A Computerized Tomography Scan (CT) or Magnetic Resonance Imaging (MRI) of the brain and orbits was required within 4 weeks prior to study entry and an ophthalmic EUA to confirm the diagnosis of a Group B intraocular tumor within 3 weeks of study entry. Patients were registered on study based on the local EUA performed for diagnostic purposes prior to study entry.
RetCam images were submitted from the diagnostic EUA for central review within 3 weeks following study entry. With assistance of the Quality Assurance Radiotherapy Center, these images were independently reviewed by three ophthalmologists, specializing in retinoblastoma management, within 6 weeks from study entry to confirm eligibility as per the International Retinoblastoma Classification System. Subsequent RetCam images were submitted and centrally reviewed, utilizing the same mechanism, during and following therapy to assess response.
Statistical methods
The primary aim of the study was to demonstrate that the proposed treatment regimen, with two-drug chemoreduction with VC, resulted in EFS of 96% at 2 years with few subsequent failures by ruling out an EFS less than 88% at 2 years. The difference between the number of observed and expected failures was approximately normally distributed with independent increments and thus could be used for interim monitoring using standard group sequential boundaries. Outcome data were formally reviewed, using the Lan-DeMets -spending function implementation of sequential boundaries, after every expected failure, corresponding approximately to 33%, 66%, and 100% of the expected information. An alpha spending function of ( t) was used, as it is of interest to detect early indications of increased harm relative to an outcome we considered sufficient for this stage of disease. 31 Accounting for a 10% drop-out rate, a target accrual of 85 patients was set in order to assure 80% power to rule out a 2-year EFS below 90%, assuming that the 2-year EFS for the current therapy was actually 96%, at a one-sided -level of 0.10.
EFS was taken as the time from enrollment to the first occurrence of an analytic event, considered to be external beam radiation therapy, enucleation of the affected eye, administration of systemic chemotherapy to control progressive disease, diagnosis of a second malignant neoplasm or death, or last contact. Patients who did not experience an analytic event by the date of last contact were considered censored for EFS; in all other cases, an EFS event was considered to have occurred.
Survival was defined as the time from enrollment to death or last contact. Patients who were alive at last contact were considered censored for survival; in all other cases, a survival event was considered to have occurred.
EFS and survival, as a function of time since enrollment, were calculated by the method of Kaplan and Meir. The distribution of the complementary log-log transformation of the Kaplan-Meier estimate was used for the construction of confidence intervals (CIs). 32 The cumulative incidence of each type of analytic event, namely, external beam radiation therapy, enucleation of the affected eye, or administration of systemic chemotherapy to control progressive disease, was calculated according to the method of Gray. 33 
RESULTS

Patients
Twenty-eight patients were registered for the study. Patients began treatment at a mean of 7.7 days from date of EUA with a range of 0-27 days. Of 41 eyes evaluated by central review, 10 (25%) central review eye group classifications disagreed with the institutional group resulting in seven patients (25%) being determined to be ineligible for the study. Of the seven patients, one was determined to have only a
F I G U R E 2 Consort diagram
Group A involved eye and the other six had an intact eye that was Group C or D. A consort diagram is shown in Figure 2 . Of the 21 eligible patients, there were 12 (57%) females and six (43%) males with the following age distribution: 12 (57%) were less than 6 months of age, six (28%) were 6 months-1 year, two (10)% were 1-2 years, and one was older than age 2 years. Distribution by sex and reported race was consistent with U.S. incidence data. 1 Details on tumor presentation, number and location of tumors, age, time to event, and follow up is shown in Table 1 , showing 10 unilateral and 11 bilateral cases. Among the bilateral cases, seven had a Group E eye that had been enucleated prior to starting protocol treatment. In these patients, the treatment success was determined solely by the response in the remaining Group B eye.
A summary of local therapies received by study patients is shown in Table 2 . 
Response and outcome
Treatment for Recurrence
Time from enrollment to last seen (years) Location of tumors: EO, from equator to ora serrata; M, macula; ME, from macula to equator. failure started therapy 10 or more days after diagnosis. The hazard ratio for an event associated with time from diagnosis to start of therapy was 0.43 (95% CI 0.12-1.5; P = 0.18). All patients who sustained a treatment failure were salvaged with additional therapy, which included enucleation, radiation therapy or additional chemotherapy, or combinations thereof. The 2-year cumulative incidence of enucleation was 15%; for external beam radiation therapy, it was 10%; and for chemotherapy to control progressive disease, it was 10%. There were no metastatic recurrences and one patient was found to have minimal episcleral disease on enucleation. No patients required bilateral enucleation.
A total of 19 patients completed therapy per protocol, with seven patients removed by physicians after study termination as they felt it to be in the patient's best interest. Details of treatment subsequent to termination of protocol therapy of these patients were not reported.
Toxicity
Therapy was well tolerated. Eight patients (38%) experienced grade 3 or 4 toxicity (using the Common Toxicity Criteria, v3), the most common of which was hematologic. There were two infections, one allergic reaction with urticaria and one case of dehydration. These toxicities were not unexpected with the chemotherapy regimen and the age of the enrolled patients.
DISCUSSION
While this study was closed due to an excess number of failures, based on an EFS of 65% compared with the projected EFS of 96%, all treatment failures were local. Overall patient survival was 100%. 
TA B L E 2 Local therapies received by patients
F I G U R E 3 Event-free survival and overall survival in ARET0331
No patients developed metastatic disease or a subsequent malignancy and no bilateral enucleations were required. Of the seven patients who entered the study with only one intact eye, there were only two failures and both were salvaged by additional systemic chemotherapy combined with local ophthalmic therapy.
Because intraocular retinoblastoma has cure rates that approach 100%, and treatment with vincristine, etoposide, and carboplatin is highly successful in patients with Group B intraocular disease, 3, [17] [18] [19] [20] [21] [22] [23] [24] our stopping criteria were particularly stringent. We also did not want an excess number of patients to be exposed to additional chemotherapy or radiotherapy, both of which are associated with significant long-term toxicities, most particularly, SMN. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, as used in this small group of patients, systemic chemotherapy with VC alone did not afford the same rate of EFS as previous published studies with vincristine, etoposide, and carboplatin. 3, [17] [18] [19] [20] [21] [22] [23] [24] This may in part be due to this being a multiinstitutional study, as opposed to single institution studies where therapies are delivered at highly specialized centers with high retinoblastoma patient volume and expertise.
Our data compare favorably to those reported by Rodriguez- the 5-year probability of encleation-free and external beam radiotherapy free survival was 0.9 and 0.41, respectively. Two patients required the addition of etoposide for ocular salvage. These data suggest that this is an acceptable regimen in developing countries with results in selected high volume centers not too dissimilar to those from this COG study. 36 While certainly advantageous to start therapy promptly after diagnosis, increased time between diagnosis and start of therapy (range 0-27 days) only nominally increased risk of an event, but this was not significant. In our study, local therapies were allowed with the second course of chemotherapy to assess response to the first course of systemic chemotherapy and correlate the response to the outcome. Thus, delays between time of diagnosis and start of treatment represented a delay in the start of systemic chemotherapy only. All patients in our study demonstrated tumor response after a single cycle of chemotherapy and all but two responded to six cycles. This is consistent with data from a study of 36 tumors measured after cycles of systemic carboplatin, where the cumulative decrease in area and diameter of tumors was greatest after one to two cycles, with less change thereafter. 37 Therefore, the delay in instituting local therapy in our study adversely affected outcome, as failures were local. It is well known that local control for most solid malignancies is optimal earlier in therapy, corresponding to the time period of optimal cytoreduction and prior to the development of chemoresistance. In addition, there appears to be a synergistic effect of the concurrent use of chemotherapy and local ophthalmic therapies. The sequential administration of carboplatin and thermotherapy enhances the antitumor effect by increasing the platinum-DNA adducts, and is commonly utilized in such a manner in the treatment of intraocular retinoblastoma. 38, 39 Cryotherapy increases the intraocular penetration of carboplatin, presumably through disruption of the blood-vitreous barrier. 40, 41 Laser ablation and diode laser hyperthermia may also act through this mechanism.
We would suggest that local therapy be applied with every cycle of systemic chemotherapy.
While the use of VC in the absence of etoposide in our study did not produce the same EFS as regimens with vincristine, etoposide, and carboplatin or carboplatin and etoposide, the balance between efficacy and potential toxicity should be considered. While etoposide can result in short-term toxicities such as myelosuppression and allergic reaction, its association with secondary leukemia was the driving motivation to attempt avoidance of its use in children with retinoblastoma.
While not absent, reports of etoposide-associated secondary leukemia in patients with retinoblastoma remain low. 9, 42 In a review by Gombos and colleagues, by physician survey and review of databases with >1,600 patients, eight cases of secondary leukemia were identified among patients receiving 360-2,700 mg/m 2 of etoposide, but all in regimens other than carboplatin, etoposide, and vincristine. 9 When considering treatment for retinoblastoma, considerations must include survival of the child, retention of the affected eye, and useful vision. Survival was 100% and ocular salvage was 85%. However, these results are somewhat limited by the lack of vision outcomes, as these were not collected as part of this clinical trial.
In summary, while this study was closed prematurely as per the statistical design, due to an excess number of failures, the EFS target was set very high. Ocular response was excellent, and the majority of patients retained their eyes and not exposed to the potential toxicities of etoposide or external beam radiotherapy. For Group B disease, when considering intravenous chemoreduction, the optimal chemoreduction therapy choice must consider that the inclusion of etoposide with VC does offer better ocular salvage and avoids the need for salvage chemotherapy. However, this consideration should be balanced with the very small but not absent risk for secondary malignancy associated with etoposide. In general, etoposide-related leukemia has been reported in cohorts of patients treated for malignancies other than retinoblastoma with higher doses than that delivered in retinoblastoma therapy, and sometimes in combination with radiotherapy. 30, 43, 44 With advances in intraarterial chemotherapy, available still only at selected centers, changes in approach to treating retinoblastoma are evolving. [25] [26] [27] [28] [29] 45, 46 It is now reasonable to consider the use of intraarterial chemotherapy for Group B eyes, as ocular salvage and disease control rates are favorable. However, chemoreduction with systemic chemotherapy together with combined local ophthalmic therapy remains an important treatment modality for children too small for an intraarterial approach or who do not have access to such therapies.
For children too small for safe delivery of intraarterial therapy, a study of 11 children (19 eyes) with RE Groups I-V demonstrated efficacy of intravenous carboplatin alone until children were 3 months of age and 6 kg. 47 
